Navigation Links
Wyeth Provides Regulatory Update on Prevnar 13* in the United States
Date:8/11/2009

sible for the greatest remaining burden of invasive disease. Prevnar has been available in the U.S. for more than nine years. It is currently available in 95 countries and more than 235 million doses have been distributed worldwide.

The Prevnar 13 submission is based on a clinical trial program of 13 core Phase 3 studies involving more than 7,000 infants and young children. To date, the company has submitted regulatory applications for Prevnar 13 in more than 50 countries spanning six continents, with filings in additional countries planned. In July, Prevenar 13*, as it is known outside the U.S., was approved in Chile for use in infants and young children.

About Pneumococcal Disease

Pneumococcal disease is complex and describes a group of illnesses all caused by the bacterium Streptococcus pneumoniae. Pneumococcal disease is the leading cause of vaccine-preventable death worldwide in children younger than 5 years of age and is estimated to cause up to one million deaths worldwide in children each year.

Pneumococcal disease affects both children and adults, and includes invasive infections such as bacteremia/sepsis and meningitis, as well as pneumonia and otitis media.

Important Safety Information for Prevnar 13*

In clinical studies, the most commonly reported adverse events in children were injection site reactions, fever, irritability, decreased appetite, and increased and/or decreased sleep. Risks are associated with all vaccines, including Prevnar 13. Hypersensitivity to any vaccine component, including diphtheria toxoid, is a contraindication to its use. As with any vaccine, Prevnar 13 may not provide 100% protection against vaccine serotypes or protect against nonvaccine serotypes.

Indication for Prevnar((R))

Prevnar(R) is indicated for act
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Wyeth Announces Stockholder Approval of Pfizer Merger at 2009 Annual Meeting
2. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
3. Wyeth Announces Holder Right to Surrender Convertible Debentures
4. Wyeth Declares Common Stock Dividend
5. New Phase 3 Data Continue to Indicate that Wyeths Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
6. Wyeth Sets Webcast and Conference Call For 2009 Second Quarter Earnings
7. Wyeth Announces Full Redemption of $2 Convertible Preferred Stock
8. Wyeth Declares Common and Preferred Stock Dividends
9. Wyeth Sets Webcast and Conference Call for 2009 First Quarter Earnings
10. Wyeth to Present at the SG Cowen & Co. 29th Annual Healthcare Conference
11. Wyeth to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... 30, 2015 , ... The 2015 Market Research Report on the Global ... the global Propanol market with a focus on the Chinese situation. Major companies included ... Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... field clinical study of its canine osteoarthritis stem cell product, currently under development ... City, KS) and will be marketed in the US by Aratana. This product, ...
(Date:7/30/2015)... --  Senomyx , Inc. (NASDAQ: SNMX ), a ... develop, and commercialize novel flavor ingredients for the food, ... for the second quarter 2015. "Moving ... track to achieve our commercial and financial goals," stated ... Company. "Since our last quarterly earnings report, our two ...
(Date:7/30/2015)... , July 30, 2015 Ascendis Pharma ... that applies its innovative TransCon technology to address ... results from a six-month Phase 2 study to ... Growth Hormone in 53 treatment-naïve, pre-pubertal children with ... are extremely pleased with the top-line results from ...
Breaking Biology Technology:Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... CBDM.T®, the market and business intelligence company, the biofuel market is ... market consists of approximately 85% bioethanol and 15% biodiesel. Bioethanol is ... other hand, Europe is the world leader in biodiesel production and ... , ...
... China, Dec. 1 /PRNewswire-Asia/ -- China Medicine ... "the Company"), a leading,developer and distributor of ... medicines (TCM), nutritional and dietary supplements, and,medical ... the Company was,awarded GSP (Good Supply Practice ...
... Global Marketing of Ciba TINOSAN SDC in Personal Care, Household ... SAN DIEGO and BASEL, Switzerland, Dec. 1 PURE Bioscience ... a new agreement with Ciba (SWX: CIBN) to market and ... biocide in the personal care, household, and industrial markets worldwide. ...
Cached Biology Technology:CBDM.T, the Market and Business Intelligence Company Reviews the Biofuel Market 2CBDM.T, the Market and Business Intelligence Company Reviews the Biofuel Market 3CBDM.T, the Market and Business Intelligence Company Reviews the Biofuel Market 4China Medicine Corporation Awarded GSP Certification 2China Medicine Corporation Awarded GSP Certification 3PURE Bioscience and Ciba Strike New Contract for Natural Antimicrobial 2PURE Bioscience and Ciba Strike New Contract for Natural Antimicrobial 3PURE Bioscience and Ciba Strike New Contract for Natural Antimicrobial 4
(Date:7/8/2015)... July 8, 2015 Summary Pancreatic cancer ... fourth most fatal, with a mortality rate of 10.9 ... of pancreatic cancer patients has highlighted a significant need ... not being met by the current market. A ... products with varying molecule types and mechanisms of action, ...
(Date:7/7/2015)... 2015 Research and ... of the "Capacitive Fingerprint Sensors Patent Landscape" ... this date, fingerprint sensing technology is the most ... are well developed. This patent landscape focuses on ... The domain of capacitive fingerprint sensors is closely ...
(Date:7/2/2015)... 25, 2015 Research and ... "Next Generation Biometrics Market by Application, Technology, Function ... to their offering. The next generation biometrics ... at a CAGR of 17.9% between 2015 and 2020 ... for the market. Safran SA ( ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... available in German . , In chemical ... of basic or fine chemicals, in catalytic converters of exhaust ... of Karlsruhe Institute of Technology (KIT) and Ruhr-Universitt Bochum (RUB) ... study processes at surfaces of oxides used as catalysts. Their ...
... the Bellvitge Biomedical Research Institute (IDIBELL) have shown that ... a higher level of the protein peroxiredoxin 2 (PRDX2). ... of this protein could be a new therapeutic strategy ... advanced in the online edition of the journal ...
... neighborhoods in which children and adolescents live and spend their ... a healthy diet, get enough exercise or become obese, concludes ... the American Journal of Preventive Medicine . ... methods in geographic information systems (GIS)-based research to determine how ...
Cached Biology News:KIT: Processes at the surface of catalysts 2Geographic information systems demonstrate links between health and location 2
Rad 50 Immunogen: c-terminal mRad 50 (604 amino acids). Storage: 4 C...
... System is ideal for developing single and ... system contains the new, improved, and user ... user can design specific templates for commercial ... fully integrated graphing and data regression capabilities; ...
...
... GeneSwitch Cell Lines stably express the ... cell line is functionally tested for ... the expression control vector pGene/V5-His/lacZ and ... treatment with mifepristone (Figure 1). These ...
Biology Products: